Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Angiotensin II receptor blockers (ARB) are known to preserve kidney function among patients
with kidney diseases and reduced renal function, but not among haemodialysis patients.
Haemodialysis patients often lose residual renal function after initiating dialysis leading
to worsened quality of life, increased morbidity and mortality.
In this study an ARB is investigated in a double blind, randomised, parallel group, placebo
controlled manner to see, if this ARB can save residual renal function among haemodialysis
patients. Potential cardiovascular benefits of the treatment are also addressed.
Phase:
Phase 3
Details
Lead Sponsor:
University of Aarhus
Treatments:
Angiotensin II Type 1 Receptor Blockers Irbesartan